S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Rocket Pharmaceuticals Stock Forecast, Price & News

+0.69 (+5.01%)
(As of 07/1/2022 08:45 PM ET)
Today's Range
50-Day Range
52-Week Range
1.01 million shs
Average Volume
653,534 shs
Market Capitalization
$951.36 million
P/E Ratio
Dividend Yield
Price Target

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
344.6% Upside
$64.25 Price Target
Short Interest
13.00% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.36mentions of Rocket Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.70) to ($2.36) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.11 out of 5 stars

Medical Sector

257th out of 1,412 stocks

Pharmaceutical Preparations Industry

124th out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Rocket Pharmaceuticals logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

RCKT Stock News Headlines

The Rhyme Rocket
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 7.3% Higher
Rocket Mortgage Review for June 2022
Analyst Ratings for Rocket Pharmaceuticals
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-169.07 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$7.05 per share


Free Float
Market Cap
$951.36 million

Rocket Pharmaceuticals Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2022?

5 Wall Street research analysts have issued twelve-month price targets for Rocket Pharmaceuticals' shares. Their RCKT stock forecasts range from $62.00 to $67.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $64.25 in the next year. This suggests a possible upside of 344.6% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Rocket Pharmaceuticals' stock performed in 2022?

Rocket Pharmaceuticals' stock was trading at $21.83 on January 1st, 2022. Since then, RCKT stock has decreased by 33.8% and is now trading at $14.45.
View the best growth stocks for 2022 here

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Rocket Pharmaceuticals

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.03. During the same period last year, the business earned ($0.65) earnings per share.
View Rocket Pharmaceuticals' earnings history

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Dr. Gaurav D. Shah M.D., CEO & Director (Age 47, Pay $920.2k)
  • Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD, Pres & COO (Age 43, Pay $717.82k)
  • Mr. Martin L. Wilson J.D., Gen. Counsel, Chief Compliance Officer & Sr. VP (Age 45, Pay $149.95k)
  • Mr. Jonathan Schwartz, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 58, Pay $557.79k)
  • Mr. John C. Militello CPA, CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer (Age 49)
  • Mayur Kasetty M.B.A., M.D., Bus. Devel. & Operations and Investor Relations Lead
  • Ms. Jessie Yeung M.B.A., VP of Investor Relations & Corp. Fin.
  • Kevin Giordano, Director of Corp. Communications
  • Ms. Isabel Carmona J.D., Sr. VP & Chief HR Officer
  • Dr. Gayatri R. Rao J.D., M.D., Chief Devel. Officer of LVV & Sr. VP

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $14.45.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $951.36 million. The biotechnology company earns $-169.07 million in net income (profit) each year or ($2.700010) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for Rocket Pharmaceuticals is www.rocketpharma.com. The biotechnology company can be reached via phone at (646) 440-9100, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.